Management of anti-Jka alloimmunization

Area of Science:

• Immunology
• Maternal-Fetal Medicine
• Neonatology

Background:

• Alloimmunization during pregnancy can lead to hemolytic disease of the fetus/newborn (HDFN).
• Guidelines for managing RhD alloimmunization are well-established.
• The applicability of these guidelines to other antibodies, such as anti-Jka, requires investigation.

Purpose of the Study:

• To assess the effectiveness of anti-D management protocols for pregnancies affected by anti-Jka antibodies.
• To determine if established prenatal monitoring strategies can identify severe HDFN caused by anti-Jka.

Main Methods:

• Retrospective review of alloimmunized pregnancies with anti-Jka from 1959-2008.
• Inclusion criteria: Jka antigen-positive newborns and available maternal records.
• Utilized maternal antibody titers and middle cerebral artery peak systolic velocity (MCA PSV) for monitoring.

Main Results:

• Twenty pregnancies met the inclusion criteria for anti-Jka alloimmunization.
• One case with high titer (32) and elevated MCA PSV required intrauterine transfusions for fetal anemia.
• Another case with titer 32 needed phototherapy for HDFN; other cases required no intervention.

Conclusions:

• Maternal antibody titer and MCA PSV monitoring, adapted from anti-D protocols, identified severe HDFN in anti-Jka pregnancies.
• Established criteria for RhD alloimmunization monitoring are effective for anti-Jka cases.
• This approach aids in detecting and managing potentially severe fetal anemia and HDFN.